Interferon alpha-2b + ribavirin

Drug Profile

Interferon alpha-2b + ribavirin

Alternative Names: Cotronak + interferon alpha-2b; Rebetol® + Intron A®; Rebetron; Rebetron combination therapy™; Ribavirin/interferon alpha-2b

Latest Information Update: 11 Aug 2015

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antivirals; Interferons; Ribonucleosides
  • Mechanism of Action Interferon alpha stimulants; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 25 Oct 2004 The CHMP has recommended extending the use of interferon-α-2b + ribavirin to the treatment of chronic hepatitis C in children over 3 years in the EU
  • 23 Jan 2004 REBETOL® oral solution for use in combination with interferon-α-2b (INTRON® A) injection for the treatment of chronic hepatitis C in patients 3 years and older has been launched in the US
  • 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top